Étiquette : hiv

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al.,

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite

Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder ?, Ben SESSA, 2017

Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder ? Ben SESSA Journal of Psychedelic Studies, 2017,  1, (1), pp. 1–9 DOI: 10.1556/2054.01.2016.003   Treating people with alcohol use disorder has been an important target area for psychedelic research – both in the first studies of the 1950s and during the Psychedelic Renaissance of the last 10 years. To date, most studies have looked at the classical psychedelic drugs as adjuncts to psychotherapy; with attention paid to the psychospiritual aspect of the experience as a central therapeutic process in effecting abstinence from drinking. Psychotherapy assisted with 3,4,-methylenedioxymethamphetamine (MDMA) has never been explored for treating [...]

Lire la suite

Bibliographie Cannabinoïdes et HIV/SIDA

Dr Christian Sueur, GRECC, août 2018. ABRAMS D.I., HILTON J.F., LEISER R.J. et al. : Short-term effects of cannabinoids in patients with HIV-1 infection : a randomized, placebo-controlled clinical trial, Annals of Internal Medicine, 2003, 139, 258-266. ABRAMS D.I., JAY C.A. et al : Cannabis in painful HIV-associated sensory neuropathy : a randomized placebo-controlled trial, Neurology, 2007, 68, 7, 515-521. ABRAMS D.I., COUEY P., SHADE S.B. et al. : Cannabinoid-Opioid Interaction in Chronic Pain, Clinical Pharmacology and Therapeutics, 2011, DOI : 10.1038/clpt.2011.188. AVRAHAM H.K. et al. : Impaired Neurogenesis by HIV-1-GP120 is rescued by genetic deletion of Fatty Acid Amide Hydrolase Enzyme, British Journal of Pharmacology, 2014. [...]

Lire la suite

Le Cannabis et les cannabinoïdes dans les pathologies HIV/SIDA

Dr Christian SUEUR, psychiatre, GRECC (Groupe de Recherches et d’Etudes Cliniques sur les Cannabinoïdes) Août 2018   Dès 1999, dans le rapport « Marijuana and Medicine : Assessing the Science Base », l’Académie de Médecine américaine affirmait le caractère thérapeutique du cannabis chez les patients atteints du SIDA : « The profile of cannabinoid drugs effects suggest that they are promising for treating wasting syndrome in AIDS patients. Nausea, appetite loss, pain and anxiety are all afflictions of wasting, and all can be mitigated by marijuana. Although some médications are more effective than marijuana for these problems, they are not equally effective in all patients. A rapid-onset (that [...]

Lire la suite